IN2012DN02714A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02714A IN2012DN02714A IN2714DEN2012A IN2012DN02714A IN 2012DN02714 A IN2012DN02714 A IN 2012DN02714A IN 2714DEN2012 A IN2714DEN2012 A IN 2714DEN2012A IN 2012DN02714 A IN2012DN02714 A IN 2012DN02714A
- Authority
- IN
- India
- Prior art keywords
- medicaments
- diseases
- excessive
- groups
- treatment
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention encompasses compounds of general formulae (1a) and (1b) wherein the groups R1 to R5, A, Q, m, n, p and q are defined as in claim 1, which are suitable for the treatment of diseases-characterised by excessive or abnormal cell proliferation, and their use as medicaments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172026 | 2009-10-02 | ||
| EP10172460 | 2010-08-11 | ||
| PCT/EP2010/064628 WO2011039344A1 (en) | 2009-10-02 | 2010-10-01 | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02714A true IN2012DN02714A (en) | 2015-09-11 |
Family
ID=43048878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2714DEN2012 IN2012DN02714A (en) | 2009-10-02 | 2010-10-01 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8466155B2 (en) |
| EP (1) | EP2483249B1 (en) |
| JP (1) | JP5702390B2 (en) |
| KR (1) | KR20120092617A (en) |
| CN (1) | CN102695700A (en) |
| AP (1) | AP2012006166A0 (en) |
| AR (1) | AR078513A1 (en) |
| AU (1) | AU2010302648A1 (en) |
| BR (1) | BR112012007300A2 (en) |
| CA (1) | CA2775418A1 (en) |
| CL (1) | CL2012000825A1 (en) |
| EA (1) | EA201200552A1 (en) |
| EC (1) | ECSP12011830A (en) |
| IL (1) | IL218543A0 (en) |
| IN (1) | IN2012DN02714A (en) |
| MA (1) | MA33606B1 (en) |
| MX (1) | MX2012003101A (en) |
| NZ (1) | NZ598614A (en) |
| PE (1) | PE20121431A1 (en) |
| PH (1) | PH12012500527A1 (en) |
| TN (1) | TN2012000142A1 (en) |
| TW (1) | TW201124386A (en) |
| UY (1) | UY32916A (en) |
| WO (1) | WO2011039344A1 (en) |
| ZA (1) | ZA201201703B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US20150132301A1 (en) * | 2011-12-09 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Combination Therapy for Treatment of Cancer |
| JPWO2013146963A1 (en) * | 2012-03-28 | 2015-12-14 | 武田薬品工業株式会社 | Heterocyclic compounds |
| PH12019502809B1 (en) | 2012-06-13 | 2024-04-24 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SMT201800127T1 (en) | 2013-04-19 | 2018-05-02 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP2999472B1 (en) | 2013-05-22 | 2020-07-22 | The Regents of The University of California | Aurora kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| MA52493A (en) | 2018-05-04 | 2021-03-10 | Incyte Corp | FGFR INHIBITOR SALTS |
| JP2021523121A (en) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Solid form of FGFR inhibitor and its preparation process |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JOP20220083A1 (en) | 2019-10-14 | 2023-01-30 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of an fgfr inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522188A (en) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Tricyclic Heterocycles as FGFR Inhibitors |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| KR100874791B1 (en) * | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | CDV-inhibited pyrimidine, preparation method thereof and use as medicament |
| EP1438053B1 (en) | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
| JP2005526765A (en) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | CDK-inhibiting 2-heteroaryl-pyrimidines, their production and use as pharmaceuticals |
| AR042486A1 (en) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | QUINOLINE AND NAFTIRIDINE COMPOSITE HALOSUSTITUDED IN POSITION 3, PROCEDURE TO PREPARE THE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION. |
| JP4812763B2 (en) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof |
| JP2008514571A (en) * | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Substituted 2-substituted anilinopyrimidines as cell cycle-kinase or receptor-tyrosine-kinase inhibitors, their preparation and use as pharmaceuticals |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2634646C (en) * | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| PE20120006A1 (en) | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | COMPOUNDS DERIVED FROM PYRIMIDINE AS INHIBITORS OF KINASE AURORA |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| WO2008077885A2 (en) * | 2006-12-22 | 2008-07-03 | Boehringer Ingelheim International Gmbh | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
| ES2465673T3 (en) | 2007-04-16 | 2014-06-06 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| KR101955914B1 (en) | 2008-06-27 | 2019-03-11 | 셀젠 카르 엘엘씨 | Heteroaryl compounds and uses thereof |
| AR074209A1 (en) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | USEFUL PYRIMIDINE DERIVATIVES FOR CANCER TREATMENT |
| CN102482277B (en) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | Epidermal growth factor receptor inhibitor and the method for treating obstacle |
-
2010
- 2010-09-29 US US12/893,240 patent/US8466155B2/en active Active
- 2010-09-30 UY UY0001032916A patent/UY32916A/en not_active Application Discontinuation
- 2010-10-01 WO PCT/EP2010/064628 patent/WO2011039344A1/en not_active Ceased
- 2010-10-01 IN IN2714DEN2012 patent/IN2012DN02714A/en unknown
- 2010-10-01 JP JP2012531442A patent/JP5702390B2/en active Active
- 2010-10-01 NZ NZ598614A patent/NZ598614A/en not_active IP Right Cessation
- 2010-10-01 PH PH1/2012/500527A patent/PH12012500527A1/en unknown
- 2010-10-01 PE PE2012000420A patent/PE20121431A1/en not_active Application Discontinuation
- 2010-10-01 AR ARP100103594A patent/AR078513A1/en unknown
- 2010-10-01 KR KR1020127011321A patent/KR20120092617A/en not_active Withdrawn
- 2010-10-01 AP AP2012006166A patent/AP2012006166A0/en unknown
- 2010-10-01 MX MX2012003101A patent/MX2012003101A/en active IP Right Grant
- 2010-10-01 CA CA2775418A patent/CA2775418A1/en not_active Abandoned
- 2010-10-01 EP EP10759924.3A patent/EP2483249B1/en active Active
- 2010-10-01 CN CN201080054924XA patent/CN102695700A/en active Pending
- 2010-10-01 EA EA201200552A patent/EA201200552A1/en unknown
- 2010-10-01 TW TW099133534A patent/TW201124386A/en unknown
- 2010-10-01 BR BR112012007300A patent/BR112012007300A2/en not_active IP Right Cessation
- 2010-10-01 AU AU2010302648A patent/AU2010302648A1/en not_active Abandoned
-
2012
- 2012-03-08 ZA ZA2012/01703A patent/ZA201201703B/en unknown
- 2012-03-08 IL IL218543A patent/IL218543A0/en unknown
- 2012-03-26 MA MA34719A patent/MA33606B1/en unknown
- 2012-03-29 TN TNP2012000142A patent/TN2012000142A1/en unknown
- 2012-04-02 CL CL2012000825A patent/CL2012000825A1/en unknown
- 2012-04-26 EC ECSP12011830 patent/ECSP12011830A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2012000142A1 (en) | 2013-09-19 |
| PH12012500527A1 (en) | 2012-10-22 |
| TW201124386A (en) | 2011-07-16 |
| CA2775418A1 (en) | 2011-04-07 |
| PE20121431A1 (en) | 2012-11-10 |
| ECSP12011830A (en) | 2012-06-29 |
| NZ598614A (en) | 2013-08-30 |
| KR20120092617A (en) | 2012-08-21 |
| US20110237598A1 (en) | 2011-09-29 |
| IL218543A0 (en) | 2012-05-31 |
| EP2483249B1 (en) | 2015-12-23 |
| BR112012007300A2 (en) | 2017-11-07 |
| WO2011039344A1 (en) | 2011-04-07 |
| MA33606B1 (en) | 2012-09-01 |
| AR078513A1 (en) | 2011-11-16 |
| CN102695700A (en) | 2012-09-26 |
| JP2013506636A (en) | 2013-02-28 |
| ZA201201703B (en) | 2014-05-28 |
| EP2483249A1 (en) | 2012-08-08 |
| JP5702390B2 (en) | 2015-04-15 |
| US8466155B2 (en) | 2013-06-18 |
| CL2012000825A1 (en) | 2012-08-24 |
| AU2010302648A1 (en) | 2012-04-05 |
| MX2012003101A (en) | 2012-04-11 |
| AP2012006166A0 (en) | 2012-04-30 |
| EA201200552A1 (en) | 2013-03-29 |
| UY32916A (en) | 2011-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02714A (en) | ||
| TN2012000369A1 (en) | 5-alkynyl-pyrimidines | |
| TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MX2011009780A (en) | Substituted pyrimidines for the treatment of cancer. | |
| PH12013500152A1 (en) | New aminopyrazoloquinazolines | |
| MX2011011661A (en) | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750. | |
| IN2015DN00960A (en) | ||
| MX2011007998A (en) | Novel herbicides. | |
| MX2009013935A (en) | New chemical compounds. | |
| MY161132A (en) | Novel herbicides | |
| PH12014502169A1 (en) | N-cyclylamides as nematicides | |
| PH12014501913A1 (en) | New 5-alkynyl pyridine | |
| MX2011012643A (en) | 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| MX2012008141A (en) | Compounds and methods. | |
| WO2009000832A3 (en) | Chemical compounds | |
| MX2011007932A (en) | Novel herbicides. | |
| UA102289C2 (en) | Herbicides obtained of cyclopentadione | |
| MX2015001099A (en) | New bicyclicpyridine derivatives. | |
| TN2011000355A1 (en) | Novel microbiocides | |
| TN2011000531A1 (en) | 5- alkynyl - pyridines | |
| MX2010009837A (en) | Thiazolyl-dihydro-indazoles. | |
| IN2012DN01223A (en) | ||
| IN2012DN02698A (en) | ||
| IN2012DN06600A (en) | ||
| PH12015501428A1 (en) | Antibacterial compounds |